The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Archive — August 2025
Page 5 of 5 of this archive, newest first.
Brazil health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.
SURMOUNT-1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Who chose the vial that was tested?
What a laboratory can and cannot know about the provenance, storage history and representativeness of what lands on its bench.
A document, not a test: what a certificate actually is
Nothing on this page is difficult. It is simply unfamiliar, and unfamiliarity is what makes a weak certificate look like a strong one.
Which results should be repeated before they are investigated
Timing is the whole of the post-cessation panel: draw it too early and it measures the treatment period.
What the new Ireland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
From the floor in Hong Kong: 18 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What a 35% rise in coupling-reagent prices does to a 30 mg vial
Follow the resin, not the catalogue.